Feasibility of (68)Ga-labeled Siglec-9 Peptide for the Imaging of Acute Lung Inflammation: a Pilot Study in a Porcine Model of Acute Respiratory Distress Syndrome
Overview
Authors
Affiliations
There is an unmet need for noninvasive, specific and quantitative imaging of inherent inflammatory activity. Vascular adhesion protein-1 (VAP-1) translocates to the luminal surface of endothelial cells upon inflammatory challenge. We hypothesized that in a porcine model of acute respiratory distress syndrome (ARDS), positron emission tomography (PET) with sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) based imaging agent targeting VAP-1 would allow quantification of regional pulmonary inflammation. ARDS was induced by lung lavages and injurious mechanical ventilation. Hemodynamics, respiratory system compliance (Crs) and blood gases were monitored. Dynamic examination using [(15)O]water PET-CT (10 min) was followed by dynamic (90 min) and whole-body examination using VAP-1 targeting (68)Ga-labeled 1,4,7,10-tetraaza cyclododecane-1,4,7-tris-acetic acid-10-ethylene glycol-conjugated Siglec-9 motif peptide ([(68)Ga]Ga-DOTA-Siglec-9). The animals received an anti-VAP-1 antibody for post-mortem immunohistochemistry assay of VAP-1 receptors. Tissue samples were collected post-mortem for the radioactivity uptake, histology and immunohistochemistry assessment. Marked reduction of oxygenation and Crs, and higher degree of inflammation were observed in ARDS animals. [(68)Ga]Ga-DOTA-Siglec-9 PET showed significant uptake in lungs, kidneys and urinary bladder. Normalization of the net uptake rate (Ki) for the tissue perfusion resulted in 4-fold higher uptake rate of [(68)Ga]Ga-DOTA-Siglec-9 in the ARDS lungs. Immunohistochemistry showed positive VAP-1 signal in the injured lungs. Detection of pulmonary inflammation associated with a porcine model of ARDS was possible with [(68)Ga]Ga-DOTA-Siglec-9 PET when using kinetic modeling and normalization for tissue perfusion.
Adventures in radiosynthesis of clinical grade [Ga]Ga-DOTA-Siglec-9.
Kakela M, Luoto P, Viljanen T, Virtanen H, Liljenback H, Jalkanen S RSC Adv. 2022; 8(15):8051-8056.
PMID: 35542034 PMC: 9078465. DOI: 10.1039/c7ra12423f.
First-in-Humans Study of Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1.
Viitanen R, Moisio O, Lankinen P, Li X, Koivumaki M, Suilamo S J Nucl Med. 2020; 62(4):577-583.
PMID: 32817143 PMC: 8049366. DOI: 10.2967/jnumed.120.250696.
Kinetic Modelling of [Ga]Ga-DOTA-Siglec-9 in Porcine Osteomyelitis and Soft Tissue Infections.
Jodal L, Roivainen A, Oikonen V, Jalkanen S, Hansen S, Afzelius P Molecules. 2019; 24(22).
PMID: 31766140 PMC: 6891593. DOI: 10.3390/molecules24224094.
Dash A, Chakravarty R Am J Nucl Med Mol Imaging. 2019; 9(1):30-66.
PMID: 30911436 PMC: 6420712.
Safety Study of Single-Dose Intravenously Administered DOTA-Siglec-9 Peptide in Sprague Dawley Rats.
Chrusciel P, Yatkin E, Li X, Jaakkola U, Knuuti J, Jalkanen S Int J Toxicol. 2019; 38(1):4-11.
PMID: 30663453 PMC: 6357174. DOI: 10.1177/1091581818821606.